Multiple sclerose en vitamine D in hoge dosis*
Uit twee studies blijkt het belang van voldoende vitamine D bij de ziekte multiple sclerose
(MS). Uit een Italiaanse studie onder 107 patiėnten waarbij een neurologische functiestoornis, een indicatie voor het begin van MS, werd vastgesteld blijkt dat hoe hoger de bloedwaarden vitamine D hoe lager de kans is om MS te ontwikkelen. Uit een Iraanse studie onder 44 personen met MS blijkt dat hoge doseringen vitamine D zonder nadelen ingenomen kunnen worden. Zes maanden lang kregen zij wekelijks 1.250 mcg vitamine D3 (dit is ruim 4x meer dan maximale dosis die Europa voorschrijft). De gemiddelde
bloedwaarden vitamine D steeg van 7,3 ng/ml (flink tekort) tot een gewenst niveau van 45,6 ng/ml en dat zonder nadelige gevolgen voor bijv. calciumwaarden.
Multiple Sclerosis Risk Lower When Vitamin D Levels Are Higher
Vitamin D, the "sunshine vitamin", is vital for health and can be obtained from food, sunlight or supplements. In addition, individuals with high vitamin D levels are less likely to develop multiple sclerosis (MS).
Now, Iranian researchers have found that vitamin D supplements at levels above the physiologically recommended dose are safe for MS patients.
Results from the study were presented at the 22nd Meeting of the European Neurological Society (ENS) in
Prague.
A neurological condition called een (CIS) is a common precursor to MS and presents itself as an episode of a vision disorder or affective sensation disorder traceable to damage in certain parts of the central nervous
system.
Doctor Vittorio Martinelli, a neurologist from San Raffaele Hospital in Milan, Italy, and his team examined the medical histories of 107 patients who had been diagnosed with CIS. The team conducted magnetic resonance images (MRIs) of the study participants, examined cerebrospinal fluid test values, the reactions to sensory stimuli in the EEG (known as multimodal Evoked Potentials), as well as the serum concentration of vitamin D3 (known as calcidiol, or 25-hydroxyvitamin D, after its conversion in the
liver).
The researchers found that 21% of study participants developed MS within 1 year, 36% developed the disease within two years, and 44% withing five years. Low vitamin D levels increase the risk of developing MS, say the researchers.
Dr Martinelli explained: "Vitamin D is even suitable for predicting MS risk in patients with clinically isolated syndrome as long as they have only a few lesions and their cerebrospinal fluid is still free of inflammation."
According to the researchers, low vitamin D levels are linked to a shorter interval between CIS and the occurrence of a second episode. In addition, it is also associated with a higher annual rate of relapse. The researchers explained:
"If inflammation occurs in the cerebrospinal fluid (oligoclonal bands), the most important predictive factors for short-term development of MS are the clinical course, multimodal Evoked Potential results and visible lesions in the
MRI."
More studies are demonstrating that vitamin D deficiency is a possible risk factor for MS. Furthermore, studies are also showing that vitamin D3 supplementation is beneficial for MS patients or for patients with other auto-immune diseases.
Another study presented at the ENS Meeting examined what risk a pharmaceutical dose of vitamin D3 poses to individuals with MS. The study was conducted by Dr Seyed Massood Nabavi from Shahed University in Teheran, Iran.
The researchers enrolled 44 patients who had been diagnosed with MS no longer than one year before to participate in the study. The patients, who showed slight functional disorders at the start of the action but no disabilities, were given a vitamin D3 dose of 50,000 IUs (international units; 1 IU=0.025 µg) per week - 4 times the daily maximum dose of 2000 IUs the European Commission
recommends.
In this group the researchers found that the concentration of calcidiol in the blood increased from 7.3 ±15 ng/ml, (severe vitamin D deficiency), to the favorable level of 45.6 ± 34.9ng/ml in the sixth month. The team also found no clinical signs of vitamin D poisoning among study participants. In addition, all patients stayed in the normal range of reference values for calcium in the blood, for creatinine, and for 24 hour urinary calcium excretions. None of the participants showed any sign of
toxicity.
The researchers said:
"The data supported the tolerability of a pharmaceutical dose of vitamin D3, at least 50,000 international units a week. In other words, vitamin D intake is safe for MS patients at levels above the physiologically recommended dose."
Medicalnewstoday (September 2012)
Reacties: